Isomorphic Labs
Health
· Headquartered in United States 🇺🇸
Track Isomorphic Labs
— get Health deals in free daily digest
Overview
Isomorphic Labs, a drug-design company spun out of Alphabet, secured a $600 million Series A funding round in March 2025, led by Thrive Capital with participation from Google Ventures. The funding aims to revolutionize drug discovery using AI, addressing the inefficiencies of traditional methods that have a 90% failure rate in clinical trials. Partnerships with Eli Lilly and Novartis focus on tackling 'undruggable' diseases like pancreatic and lung cancers, although Isomorphic has yet to advance any drugs to clinical trials as of January 2026.
Products
Loading...
Synthesising company profile
Reading press coverage to extract founders, customers, traction signals and competitive positioning…
Recent Announcements
Investors: Thrive Capital, Google Ventures
Isomorphic Labs, a drug-design company spun out of Alphabet, secured a $600 million Series A funding round in March 2025, led by Thrive Capital with participation from Google Ventures. The funding aims to revolutionize drug discovery using AI, addressing the inefficiencies of traditional methods that have a 90% failure rate in clinical trials. Partnerships with Eli Lilly and Novartis focus on tackling 'undruggable' diseases like pancreatic and lung cancers, although Isomorphic has yet to advance any drugs to clinical trials as of January 2026.
More Health Deals
Market Map
View thousands of companies by category in our market map:
